
Operations Office

Telephone (507) 284-4852



Date: May 27, 2005

To: Primary Clinical Research Associates

From: Janis Gjervik
Protocol Development Coordinator

Re: N0321, Phase I/II Study of PS-341 in Combination with Paclitaxel, Carboplatin, and Concurrent Thoracic Radiation Therapy for Non-small Cell Lung Cancer (NSCLC)

The following forms (distributed with Addendum 1) need to be implemented as soon as possible, without waiting until you have IRB approval of Addendum 1:

- Nadir/Adverse Event Log (11/4/04)
- Dose-Limiting Toxicity Reporting Form (11/4/04)

If you have any questions, please feel free to contact me.